Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the Altimmune ( NASDAQ:ALT ) First Half 2024 Results Key Financial Results Net loss ...
The Los Angeles Chargers dropped a challenging game on Sunday, losing their first game of the season to the Pittsburgh Steelers, 20-10. The Chargers struggled ...